Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy

Abstract

Our finding suggest that certain clinicopathological and immunohistochemical variables, particularly p53 expression, may serve as indicators of BCC response to MAL-PDT, and thus facilitate the selection of patients who are most likely to benefit from this therapy.